An Arterial Hypertension Diagnosis And Its Treatment During Covid-19

Abstract

SARS-CoV-2-infected As a result of the new corona virus infection's quick spread, COVID-19 has now developed into a pandemic that has affected people all across the world. Because of the high fatality and morbidity rates associated with the virus, additional research is being conducted to uncover potential risk factors for the outcomes of patients. Patients diagnosed with COVID-19 are more likely to suffer from hypertension, a condition that has been associated with an increased risk of death as well as hospitalisation. When a pilot investigation indicated that rennin angiotenin aldosterone system inhibitors could potentially raise the risk of viral infection and aggravate the severity of illness, medical professionals all over the world expressed alarm. This was due to the high prevalence of hypertension. Antihypertensive drugs, on the other hand, have been demonstrated to have a beneficial effect on COVID-19 infection in people who have hypertension. This is the case despite earlier research predicting that antihypertensive medicines would have the opposite effect. At the time that this article was written, it was not known how patients infected with COVID-19 would be affected by hypertension (high blood pressure). In this mini-review, which discusses the etiology of SARS-CoV-2 infection and hypertension, we find that alterations in Angiotensin converting enzyme 2 (ACE2) and RAAS play dual roles in COVID-19 and hypertension. Their individual functions are essential to the whole. There is a connection between the release of pro inflammatory chemicals and the immune response as well as gastrointestinal issues caused by COVID-19.